cohortId,targetId,targetName,strataId,strataName,cohortType
101,101,new PCa,0,All,Target
102,102,new PCa actively treated,0,All,Target
103,103,new PCa conservative management,0,All,Target
104,104,new PCa treatment post conservative management,0,All,Target
101003012,101,new PCa,301,without High-Risk,TwoS
102003012,102,new PCa actively treated,301,without High-Risk,TwoS
103003012,103,new PCa conservative management,301,without High-Risk,TwoS
104003012,104,new PCa treatment post conservative management,301,without High-Risk,TwoS
101003022,101,new PCa,302,without Low-Risk,TwoS
102003022,102,new PCa actively treated,302,without Low-Risk,TwoS
103003022,103,new PCa conservative management,302,without Low-Risk,TwoS
104003022,104,new PCa treatment post conservative management,302,without Low-Risk,TwoS
101003032,101,new PCa,303,without Intermediate-Risk,TwoS
102003032,102,new PCa actively treated,303,without Intermediate-Risk,TwoS
103003032,103,new PCa conservative management,303,without Intermediate-Risk,TwoS
104003032,104,new PCa treatment post conservative management,303,without Intermediate-Risk,TwoS
101003042,101,new PCa,304,without Metastatic Dx Extent,TwoS
102003042,102,new PCa actively treated,304,without Metastatic Dx Extent,TwoS
103003042,103,new PCa conservative management,304,without Metastatic Dx Extent,TwoS
104003042,104,new PCa treatment post conservative management,304,without Metastatic Dx Extent,TwoS
101003052,101,new PCa,305,without Locally advanced Dx Extent,TwoS
102003052,102,new PCa actively treated,305,without Locally advanced Dx Extent,TwoS
103003052,103,new PCa conservative management,305,without Locally advanced Dx Extent,TwoS
104003052,104,new PCa treatment post conservative management,305,without Locally advanced Dx Extent,TwoS
101003062,101,new PCa,306,without Localized Dx Extent,TwoS
102003062,102,new PCa actively treated,306,without Localized Dx Extent,TwoS
103003062,103,new PCa conservative management,306,without Localized Dx Extent,TwoS
104003062,104,new PCa treatment post conservative management,306,without Localized Dx Extent,TwoS
101003072,101,new PCa,307,without PSA greater than 20,TwoS
102003072,102,new PCa actively treated,307,without PSA greater than 20,TwoS
103003072,103,new PCa conservative management,307,without PSA greater than 20,TwoS
104003072,104,new PCa treatment post conservative management,307,without PSA greater than 20,TwoS
101003082,101,new PCa,308,without PSA less than 10,TwoS
102003082,102,new PCa actively treated,308,without PSA less than 10,TwoS
103003082,103,new PCa conservative management,308,without PSA less than 10,TwoS
104003082,104,new PCa treatment post conservative management,308,without PSA less than 10,TwoS
101003092,101,new PCa,309,without PSA 10-20,TwoS
102003092,102,new PCa actively treated,309,without PSA 10-20,TwoS
103003092,103,new PCa conservative management,309,without PSA 10-20,TwoS
104003092,104,new PCa treatment post conservative management,309,without PSA 10-20,TwoS
101003102,101,new PCa,310,without Stage T1,TwoS
102003102,102,new PCa actively treated,310,without Stage T1,TwoS
103003102,103,new PCa conservative management,310,without Stage T1,TwoS
104003102,104,new PCa treatment post conservative management,310,without Stage T1,TwoS
101003112,101,new PCa,311,without Stage T2,TwoS
102003112,102,new PCa actively treated,311,without Stage T2,TwoS
103003112,103,new PCa conservative management,311,without Stage T2,TwoS
104003112,104,new PCa treatment post conservative management,311,without Stage T2,TwoS
101003122,101,new PCa,312,without Stage T3,TwoS
102003122,102,new PCa actively treated,312,without Stage T3,TwoS
103003122,103,new PCa conservative management,312,without Stage T3,TwoS
104003122,104,new PCa treatment post conservative management,312,without Stage T3,TwoS
101003132,101,new PCa,313,without Stage T4,TwoS
102003132,102,new PCa actively treated,313,without Stage T4,TwoS
103003132,103,new PCa conservative management,313,without Stage T4,TwoS
104003132,104,new PCa treatment post conservative management,313,without Stage T4,TwoS
101003142,101,new PCa,314,without Grade 1 (GS 2-6),TwoS
102003142,102,new PCa actively treated,314,without Grade 1 (GS 2-6),TwoS
103003142,103,new PCa conservative management,314,without Grade 1 (GS 2-6),TwoS
104003142,104,new PCa treatment post conservative management,314,without Grade 1 (GS 2-6),TwoS
101003152,101,new PCa,315,without Grade 2 (GS 7 (3+4)),TwoS
102003152,102,new PCa actively treated,315,without Grade 2 (GS 7 (3+4)),TwoS
103003152,103,new PCa conservative management,315,without Grade 2 (GS 7 (3+4)),TwoS
104003152,104,new PCa treatment post conservative management,315,without Grade 2 (GS 7 (3+4)),TwoS
101003162,101,new PCa,316,without Grade 3 (GS 7 (4+3)),TwoS
102003162,102,new PCa actively treated,316,without Grade 3 (GS 7 (4+3)),TwoS
103003162,103,new PCa conservative management,316,without Grade 3 (GS 7 (4+3)),TwoS
104003162,104,new PCa treatment post conservative management,316,without Grade 3 (GS 7 (4+3)),TwoS
101003172,101,new PCa,317,without Grade 4 (GS 8),TwoS
102003172,102,new PCa actively treated,317,without Grade 4 (GS 8),TwoS
103003172,103,new PCa conservative management,317,without Grade 4 (GS 8),TwoS
104003172,104,new PCa treatment post conservative management,317,without Grade 4 (GS 8),TwoS
101003182,101,new PCa,318,without Grade 5 (GS 9-10),TwoS
102003182,102,new PCa actively treated,318,without Grade 5 (GS 9-10),TwoS
103003182,103,new PCa conservative management,318,without Grade 5 (GS 9-10),TwoS
104003182,104,new PCa treatment post conservative management,318,without Grade 5 (GS 9-10),TwoS
101003192,101,new PCa,319,without Family History of PCa,TwoS
102003192,102,new PCa actively treated,319,without Family History of PCa,TwoS
103003192,103,new PCa conservative management,319,without Family History of PCa,TwoS
104003192,104,new PCa treatment post conservative management,319,without Family History of PCa,TwoS
101003202,101,new PCa,320,without Total Cardiovascular Disease Event,TwoS
102003202,102,new PCa actively treated,320,without Total Cardiovascular Disease Event,TwoS
103003202,103,new PCa conservative management,320,without Total Cardiovascular Disease Event,TwoS
104003202,104,new PCa treatment post conservative management,320,without Total Cardiovascular Disease Event,TwoS
101003212,101,new PCa,321,without Stroke,TwoS
102003212,102,new PCa actively treated,321,without Stroke,TwoS
103003212,103,new PCa conservative management,321,without Stroke,TwoS
104003212,104,new PCa treatment post conservative management,321,without Stroke,TwoS
101003222,101,new PCa,322,without Type 2 Diabetes,TwoS
102003222,102,new PCa actively treated,322,without Type 2 Diabetes,TwoS
103003222,103,new PCa conservative management,322,without Type 2 Diabetes,TwoS
104003222,104,new PCa treatment post conservative management,322,without Type 2 Diabetes,TwoS
101003232,101,new PCa,323,without Any malignancy except malignant neoplasm of skin,TwoS
102003232,102,new PCa actively treated,323,without Any malignancy except malignant neoplasm of skin,TwoS
103003232,103,new PCa conservative management,323,without Any malignancy except malignant neoplasm of skin,TwoS
104003232,104,new PCa treatment post conservative management,323,without Any malignancy except malignant neoplasm of skin,TwoS
101003242,101,new PCa,324,without Hypertension,TwoS
102003242,102,new PCa actively treated,324,without Hypertension,TwoS
103003242,103,new PCa conservative management,324,without Hypertension,TwoS
104003242,104,new PCa treatment post conservative management,324,without Hypertension,TwoS
101003252,101,new PCa,325,without Obesity,TwoS
102003252,102,new PCa actively treated,325,without Obesity,TwoS
103003252,103,new PCa conservative management,325,without Obesity,TwoS
104003252,104,new PCa treatment post conservative management,325,without Obesity,TwoS
101003262,101,new PCa,326,without Venous thromboembolism,TwoS
102003262,102,new PCa actively treated,326,without Venous thromboembolism,TwoS
103003262,103,new PCa conservative management,326,without Venous thromboembolism,TwoS
104003262,104,new PCa treatment post conservative management,326,without Venous thromboembolism,TwoS
101000011,101,new PCa,1,with Full 30-day follow up,TwS
102000011,102,new PCa actively treated,1,with Full 30-day follow up,TwS
103000011,103,new PCa conservative management,1,with Full 30-day follow up,TwS
104000011,104,new PCa treatment post conservative management,1,with Full 30-day follow up,TwS
101000021,101,new PCa,2,with < 30-day follow up,TwS
102000021,102,new PCa actively treated,2,with < 30-day follow up,TwS
103000021,103,new PCa conservative management,2,with < 30-day follow up,TwS
104000021,104,new PCa treatment post conservative management,2,with < 30-day follow up,TwS
101000031,101,new PCa,3,with Sex = Female,TwS
102000031,102,new PCa actively treated,3,with Sex = Female,TwS
103000031,103,new PCa conservative management,3,with Sex = Female,TwS
104000031,104,new PCa treatment post conservative management,3,with Sex = Female,TwS
101000041,101,new PCa,4,with Sex = Male,TwS
102000041,102,new PCa actively treated,4,with Sex = Male,TwS
103000041,103,new PCa conservative management,4,with Sex = Male,TwS
104000041,104,new PCa treatment post conservative management,4,with Sex = Male,TwS
101000051,101,new PCa,5,with Age >= 18,TwS
102000051,102,new PCa actively treated,5,with Age >= 18,TwS
103000051,103,new PCa conservative management,5,with Age >= 18,TwS
104000051,104,new PCa treatment post conservative management,5,with Age >= 18,TwS
101000061,101,new PCa,6,with Age < 18,TwS
102000061,102,new PCa actively treated,6,with Age < 18,TwS
103000061,103,new PCa conservative management,6,with Age < 18,TwS
104000061,104,new PCa treatment post conservative management,6,with Age < 18,TwS
101000071,101,new PCa,7,with Age >= 65,TwS
102000071,102,new PCa actively treated,7,with Age >= 65,TwS
103000071,103,new PCa conservative management,7,with Age >= 65,TwS
104000071,104,new PCa treatment post conservative management,7,with Age >= 65,TwS
101000081,101,new PCa,8,with Age < 65,TwS
102000081,102,new PCa actively treated,8,with Age < 65,TwS
103000081,103,new PCa conservative management,8,with Age < 65,TwS
104000081,104,new PCa treatment post conservative management,8,with Age < 65,TwS
101000091,101,new PCa,9,with Black or African American,TwS
102000091,102,new PCa actively treated,9,with Black or African American,TwS
103000091,103,new PCa conservative management,9,with Black or African American,TwS
104000091,104,new PCa treatment post conservative management,9,with Black or African American,TwS
101000101,101,new PCa,10,with White,TwS
102000101,102,new PCa actively treated,10,with White,TwS
103000101,103,new PCa conservative management,10,with White,TwS
104000101,104,new PCa treatment post conservative management,10,with White,TwS
101003011,101,new PCa,301,with High-Risk,TwS
102003011,102,new PCa actively treated,301,with High-Risk,TwS
103003011,103,new PCa conservative management,301,with High-Risk,TwS
104003011,104,new PCa treatment post conservative management,301,with High-Risk,TwS
101003021,101,new PCa,302,with Low-Risk,TwS
102003021,102,new PCa actively treated,302,with Low-Risk,TwS
103003021,103,new PCa conservative management,302,with Low-Risk,TwS
104003021,104,new PCa treatment post conservative management,302,with Low-Risk,TwS
101003031,101,new PCa,303,with Intermediate-Risk,TwS
102003031,102,new PCa actively treated,303,with Intermediate-Risk,TwS
103003031,103,new PCa conservative management,303,with Intermediate-Risk,TwS
104003031,104,new PCa treatment post conservative management,303,with Intermediate-Risk,TwS
101003041,101,new PCa,304,with Metastatic Dx Extent,TwS
102003041,102,new PCa actively treated,304,with Metastatic Dx Extent,TwS
103003041,103,new PCa conservative management,304,with Metastatic Dx Extent,TwS
104003041,104,new PCa treatment post conservative management,304,with Metastatic Dx Extent,TwS
101003051,101,new PCa,305,with Locally advanced Dx Extent,TwS
102003051,102,new PCa actively treated,305,with Locally advanced Dx Extent,TwS
103003051,103,new PCa conservative management,305,with Locally advanced Dx Extent,TwS
104003051,104,new PCa treatment post conservative management,305,with Locally advanced Dx Extent,TwS
101003061,101,new PCa,306,with Localized Dx Extent,TwS
102003061,102,new PCa actively treated,306,with Localized Dx Extent,TwS
103003061,103,new PCa conservative management,306,with Localized Dx Extent,TwS
104003061,104,new PCa treatment post conservative management,306,with Localized Dx Extent,TwS
101003071,101,new PCa,307,with PSA greater than 20,TwS
102003071,102,new PCa actively treated,307,with PSA greater than 20,TwS
103003071,103,new PCa conservative management,307,with PSA greater than 20,TwS
104003071,104,new PCa treatment post conservative management,307,with PSA greater than 20,TwS
101003081,101,new PCa,308,with PSA less than 10,TwS
102003081,102,new PCa actively treated,308,with PSA less than 10,TwS
103003081,103,new PCa conservative management,308,with PSA less than 10,TwS
104003081,104,new PCa treatment post conservative management,308,with PSA less than 10,TwS
101003091,101,new PCa,309,with PSA 10-20,TwS
102003091,102,new PCa actively treated,309,with PSA 10-20,TwS
103003091,103,new PCa conservative management,309,with PSA 10-20,TwS
104003091,104,new PCa treatment post conservative management,309,with PSA 10-20,TwS
101003101,101,new PCa,310,with Stage T1,TwS
102003101,102,new PCa actively treated,310,with Stage T1,TwS
103003101,103,new PCa conservative management,310,with Stage T1,TwS
104003101,104,new PCa treatment post conservative management,310,with Stage T1,TwS
101003111,101,new PCa,311,with Stage T2,TwS
102003111,102,new PCa actively treated,311,with Stage T2,TwS
103003111,103,new PCa conservative management,311,with Stage T2,TwS
104003111,104,new PCa treatment post conservative management,311,with Stage T2,TwS
101003121,101,new PCa,312,with Stage T3,TwS
102003121,102,new PCa actively treated,312,with Stage T3,TwS
103003121,103,new PCa conservative management,312,with Stage T3,TwS
104003121,104,new PCa treatment post conservative management,312,with Stage T3,TwS
101003131,101,new PCa,313,with Stage T4,TwS
102003131,102,new PCa actively treated,313,with Stage T4,TwS
103003131,103,new PCa conservative management,313,with Stage T4,TwS
104003131,104,new PCa treatment post conservative management,313,with Stage T4,TwS
101003141,101,new PCa,314,with Grade 1 (GS 2-6),TwS
102003141,102,new PCa actively treated,314,with Grade 1 (GS 2-6),TwS
103003141,103,new PCa conservative management,314,with Grade 1 (GS 2-6),TwS
104003141,104,new PCa treatment post conservative management,314,with Grade 1 (GS 2-6),TwS
101003151,101,new PCa,315,with Grade 2 (GS 7 (3+4)),TwS
102003151,102,new PCa actively treated,315,with Grade 2 (GS 7 (3+4)),TwS
103003151,103,new PCa conservative management,315,with Grade 2 (GS 7 (3+4)),TwS
104003151,104,new PCa treatment post conservative management,315,with Grade 2 (GS 7 (3+4)),TwS
101003161,101,new PCa,316,with Grade 3 (GS 7 (4+3)),TwS
102003161,102,new PCa actively treated,316,with Grade 3 (GS 7 (4+3)),TwS
103003161,103,new PCa conservative management,316,with Grade 3 (GS 7 (4+3)),TwS
104003161,104,new PCa treatment post conservative management,316,with Grade 3 (GS 7 (4+3)),TwS
101003171,101,new PCa,317,with Grade 4 (GS 8),TwS
102003171,102,new PCa actively treated,317,with Grade 4 (GS 8),TwS
103003171,103,new PCa conservative management,317,with Grade 4 (GS 8),TwS
104003171,104,new PCa treatment post conservative management,317,with Grade 4 (GS 8),TwS
101003181,101,new PCa,318,with Grade 5 (GS 9-10),TwS
102003181,102,new PCa actively treated,318,with Grade 5 (GS 9-10),TwS
103003181,103,new PCa conservative management,318,with Grade 5 (GS 9-10),TwS
104003181,104,new PCa treatment post conservative management,318,with Grade 5 (GS 9-10),TwS
101003191,101,new PCa,319,with Family History of PCa,TwS
102003191,102,new PCa actively treated,319,with Family History of PCa,TwS
103003191,103,new PCa conservative management,319,with Family History of PCa,TwS
104003191,104,new PCa treatment post conservative management,319,with Family History of PCa,TwS
101003201,101,new PCa,320,with Total Cardiovascular Disease Event,TwS
102003201,102,new PCa actively treated,320,with Total Cardiovascular Disease Event,TwS
103003201,103,new PCa conservative management,320,with Total Cardiovascular Disease Event,TwS
104003201,104,new PCa treatment post conservative management,320,with Total Cardiovascular Disease Event,TwS
101003211,101,new PCa,321,with Stroke,TwS
102003211,102,new PCa actively treated,321,with Stroke,TwS
103003211,103,new PCa conservative management,321,with Stroke,TwS
104003211,104,new PCa treatment post conservative management,321,with Stroke,TwS
101003221,101,new PCa,322,with Type 2 Diabetes,TwS
102003221,102,new PCa actively treated,322,with Type 2 Diabetes,TwS
103003221,103,new PCa conservative management,322,with Type 2 Diabetes,TwS
104003221,104,new PCa treatment post conservative management,322,with Type 2 Diabetes,TwS
101003231,101,new PCa,323,with Any malignancy except malignant neoplasm of skin,TwS
102003231,102,new PCa actively treated,323,with Any malignancy except malignant neoplasm of skin,TwS
103003231,103,new PCa conservative management,323,with Any malignancy except malignant neoplasm of skin,TwS
104003231,104,new PCa treatment post conservative management,323,with Any malignancy except malignant neoplasm of skin,TwS
101003241,101,new PCa,324,with Hypertension,TwS
102003241,102,new PCa actively treated,324,with Hypertension,TwS
103003241,103,new PCa conservative management,324,with Hypertension,TwS
104003241,104,new PCa treatment post conservative management,324,with Hypertension,TwS
101003251,101,new PCa,325,with Obesity,TwS
102003251,102,new PCa actively treated,325,with Obesity,TwS
103003251,103,new PCa conservative management,325,with Obesity,TwS
104003251,104,new PCa treatment post conservative management,325,with Obesity,TwS
101003261,101,new PCa,326,with Venous thromboembolism,TwS
102003261,102,new PCa actively treated,326,with Venous thromboembolism,TwS
103003261,103,new PCa conservative management,326,with Venous thromboembolism,TwS
104003261,104,new PCa treatment post conservative management,326,with Venous thromboembolism,TwS
